119 related articles for article (PubMed ID: 7560169)
1. Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue.
Buist MR; Molthoff CF; Kenemans P; Meijer CJ
J Clin Pathol; 1995 Jul; 48(7):631-6. PubMed ID: 7560169
[TBL] [Abstract][Full Text] [Related]
2. Immunocytochemical detection of ovarian carcinoma cells in serous effusions.
Cuijpers VM; Boerman OC; Salet van de Pol MR; Vooijs GP; Poels LG; Ramaekers FC
Acta Cytol; 1993; 37(3):272-9. PubMed ID: 8498129
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody against human ovarian tumor-associated antigens.
Poels LG; Peters D; van Megen Y; Vooijs GP; Verheyen RN; Willemen A; van Niekerk CC; Jap PH; Mungyer G; Kenemans P
J Natl Cancer Inst; 1986 May; 76(5):781-91. PubMed ID: 3517452
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR.
van Ravenswaay Claasen HH; Eggermont AM; Nooyen YA; Warnaar SO; Fieuren GJ
Gynecol Oncol; 1994 Feb; 52(2):199-206. PubMed ID: 8314139
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies that discriminate between human ovarian carcinomas and benign ovarian tumours.
Boerman OC; Makkink WK; Thomas CM; Hanselaar AG; Yedema CA; Kenemans P; Poels LG
Eur J Cancer; 1990 Feb; 26(2):117-27. PubMed ID: 2138906
[TBL] [Abstract][Full Text] [Related]
6. Comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens.
Boerman OC; van Niekerk CC; Makkink K; Hanselaar TG; Kenemans P; Poels LG
Int J Gynecol Pathol; 1991; 10(1):15-25. PubMed ID: 2007534
[TBL] [Abstract][Full Text] [Related]
7. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein.
Coney LR; Tomassetti A; Carayannopoulos L; Frasca V; Kamen BA; Colnaghi MI; Zurawski VR
Cancer Res; 1991 Nov; 51(22):6125-32. PubMed ID: 1840502
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies against ovarian carcinoma-associated antigens, raised by immunization with cyst fluids.
Boerman O; Makkink K; Massuger L; Thomas C; Kenemans P; Hanselaar T; Poels L
Anticancer Res; 1989; 9(3):551-8. PubMed ID: 2764501
[TBL] [Abstract][Full Text] [Related]
9. Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays.
Buist MR; Kenemans P; van Kamp GJ; Haisma HJ
Cancer Immunol Immunother; 1995 Jan; 40(1):24-30. PubMed ID: 7828165
[TBL] [Abstract][Full Text] [Related]
10. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19.
Mantovani LT; Miotti S; Ménard S; Canevari S; Raspagliesi F; Bottini C; Bottero F; Colnaghi MI
Eur J Cancer; 1994; 30A(3):363-9. PubMed ID: 8204360
[TBL] [Abstract][Full Text] [Related]
11. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity.
Miotti S; Canevari S; Ménard S; Mezzanzanica D; Porro G; Pupa SM; Regazzoni M; Tagliabue E; Colnaghi MI
Int J Cancer; 1987 Mar; 39(3):297-303. PubMed ID: 2434438
[TBL] [Abstract][Full Text] [Related]
12. Normal tissue reactivity of four anti-tumor monoclonal antibodies of clinical interest.
Stein R; Goldenberg DM; Mattes MJ
Int J Cancer; 1991 Jan; 47(2):163-9. PubMed ID: 1988361
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro binding characteristics and biodistribution in tumor-bearing athymic mice of anti-ovarian carcinoma monoclonal antibodies.
Boerman O; Massuger L; Makkink K; Thomas C; Kenemans P; Poels L
Anticancer Res; 1990; 10(5A):1289-95. PubMed ID: 2241105
[TBL] [Abstract][Full Text] [Related]
14. Tumor uptake of intravenously administered radiolabeled antibodies in ovarian carcinoma patients in relation to antigen expression and other tumor characteristics.
Buist MR; Kenemans P; Molthoff CF; Roos JC; Den Hollander W; Brinkhuis M; Baak JP
Int J Cancer; 1995 Apr; 64(2):92-8. PubMed ID: 7615359
[TBL] [Abstract][Full Text] [Related]
15. Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p.
van Zanten-Przybysz I; Molthoff CF; Roos JC; Verheijen RH; van Hof A; Buist MR; Prinssen HM; den Hollander W; Kenemans P
Int J Cancer; 2001 Apr; 92(1):106-14. PubMed ID: 11279613
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of epithelial ovarian neoplasm immunologic reactivity using monoclonal antibodies].
Bar J; Sobańska E
Ginekol Pol; 1994 Sep; 65(9):502-7. PubMed ID: 7721163
[TBL] [Abstract][Full Text] [Related]
17. Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen.
Molthoff CF; Buist MR; Kenemans P; Pinedo HM; Boven E
J Nucl Med; 1992 Nov; 33(11):2000-5. PubMed ID: 1432162
[TBL] [Abstract][Full Text] [Related]
18. In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice.
Nässander UK; Steerenberg PA; Poppe H; Storm G; Poels LG; De Jong WH; Crommelin DJ
Cancer Res; 1992 Feb; 52(3):646-53. PubMed ID: 1732053
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.
Andersson H; Lindegren S; Back T; Jacobsson L; Leser G; Horvath G
Anticancer Res; 2000; 20(1A):459-62. PubMed ID: 10769696
[TBL] [Abstract][Full Text] [Related]
20. Analysis of production, purification, and cytolytic potential of bi-specific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3.
van Ravenswaay Claasen HH; van de Griend RJ; Mezzanzanica D; Bolhuis RL; Warnaar SO; Fleuren GJ
Int J Cancer; 1993 Aug; 55(1):128-36. PubMed ID: 8344744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
